Immune checkpoint inhibitors in cancer immunotherapy
- PMID: 32540906
- PMCID: PMC7828839
- DOI: 10.1503/cmaj.191231
Immune checkpoint inhibitors in cancer immunotherapy
Conflict of interest statement
Competing interests: Samuel Saibil has received personal fees from Janssen and Novartis outside the submitted work. No other competing interests were declared.
Similar articles
-
Development of Immunotherapy Combination Strategies in Cancer.Cancer Discov. 2021 Jun;11(6):1368-1397. doi: 10.1158/2159-8290.CD-20-1209. Epub 2021 Apr 2. Cancer Discov. 2021. PMID: 33811048 Free PMC article. Review.
-
How to select cancer patients for immunotherapy.EBioMedicine. 2021 Jan;63:103184. doi: 10.1016/j.ebiom.2020.103184. Epub 2021 Jan 6. EBioMedicine. 2021. PMID: 33418504 Free PMC article. No abstract available.
-
Immune-gene signature: a new tool for patient selection for checkpoint inhibitors?Future Oncol. 2020 Jul;16(19):1327-1330. doi: 10.2217/fon-2020-0311. Epub 2020 May 12. Future Oncol. 2020. PMID: 32396404 No abstract available.
-
Immunotherapy in Older Adults With Cancer.J Clin Oncol. 2021 Jul 1;39(19):2115-2127. doi: 10.1200/JCO.21.00138. Epub 2021 May 27. J Clin Oncol. 2021. PMID: 34043444 Free PMC article. Review. No abstract available.
-
Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.Int J Nanomedicine. 2021 Feb 22;16:1435-1456. doi: 10.2147/IJN.S285999. eCollection 2021. Int J Nanomedicine. 2021. PMID: 33654395 Free PMC article. Review.
Cited by
-
Identification of Novel Molecular Therapeutic Targets and Their Potential Prognostic Biomarkers Based on Cytolytic Activity in Skin Cutaneous Melanoma.Front Oncol. 2022 Mar 8;12:844666. doi: 10.3389/fonc.2022.844666. eCollection 2022. Front Oncol. 2022. PMID: 35345444 Free PMC article.
-
Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors.Int J Mol Sci. 2021 Mar 5;22(5):2608. doi: 10.3390/ijms22052608. Int J Mol Sci. 2021. PMID: 33807608 Free PMC article. Review.
-
PD-L1 regulates tumor proliferation and T-cell function in NF2-associated meningiomas.CNS Neurosci Ther. 2024 Jun;30(6):e14784. doi: 10.1111/cns.14784. CNS Neurosci Ther. 2024. PMID: 38828669 Free PMC article.
-
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis.J Oncol. 2023 Jan 7;2023:2525903. doi: 10.1155/2023/2525903. eCollection 2023. J Oncol. 2023. PMID: 36647390 Free PMC article. Review.
-
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions.J Nanobiotechnology. 2023 Jul 7;21(1):212. doi: 10.1186/s12951-023-01977-1. J Nanobiotechnology. 2023. PMID: 37415161 Free PMC article. Review.
References
-
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019;381:1535–46. - PubMed
-
- SEER stat fact sheets: melanoma of the skin. Bethesda (MD): National Cancer Institute, Surveillance Epidemiology and End Results (SEER) Program; 2016. Available: https://seer.cancer.gov/statfacts/html/melan.html (accessed 2020 May 31).
-
- Immune checkpoint inhibitor toxicity: clinical practice guideline. Toronto: Cancer Care Ontario; 2018. Available: www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/52976 (accessed 2020 May 31).
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical